 | Up a level |
Ang, C.H. and Gan, G.G. and Nadarajan, V. (2010) Suppressor of cytokine signaling 3 is down-regulated by BCR-ABL and results in loss of JAK2 V617F in a patient with concurrent BCR-ABL translocation and JAK2 V617F mutation. Haematologica-The Hematology Journal, 95 (2). pp. 402-403.
Ang, C.H. and Phan, C.L. and Gan, G.G. and Sultan, M.S. and Nadarajan, V. (2010) High resolution melt curve analysis as a tool for screening tyrosine kinase domain mutations in patients with chronic myeloid leukemia on tyrosine kinase inhibitors. Haematologica-The Hematology Journal, 95 (2). p. 335.
Ang, C.H. and Phan, C.L. and Gan, G.G. and Sultan, M.S. and Nadarajan, V. (2010) The roles of ceramide generating and ceramide clearence genes in apoptosis in chronic myeloid leukemia cells exposed to dasatinib. Haematologica-The Hematology Journal, 95 (2). pp. 335-336.
Cappellini, M.D. and Elalfy, M. and El-Beshlawy, A. and Kattamis, A. and Chan, L.L. and Li, C. and Lin, K.H. and Quarta, G. and Sutcharitchan, P. and Taher, A. and Habr, D. and Roubert, B. and Porter, J. (2010) Efficacy of deferasirox in patients with thalassaemia major is not affected by a history of hepatitis B OR C. Haematologica-The Hematology Journal, 95 (2). pp. 718-719.
Cappellini, M.D. and Porter, J. and El-Beshlawy, A. and Li, C.K. and Seymour, J.F. and Elalfy, M. and Gattermann, N. and Giraudier, S. and Lee, J.W. and Chan, L.L. and Lin, K.H. and Rose, C. and Taher, A. and Thein, S.L. and Viprakasit, V. and Habr, D. and Domokos, G. and Roubert, B. and Kattamis, A. and Investigators, EPIC Study (2010) Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica-The Hematology Journal, 95 (4). pp. 557-566.
Nadarajan, S. and Subramaniam, R. and Gan, G.G. (2010) The IL-12B 3 ` UTR (-1188 A/C) polymorphism is associated with survival outcome of hematopoietic stem cell transplants. Haematologica-The Hematology Journal, 95 (2). pp. 643-644.
Pennell, D. and Porter, J. and Cappellini, M. and Chan, L.L. and El-Beshlawy, A. and Aydinok, Y. and Ibrahim, H. and Li, C.K. and Viprakasit, V. and Elalfy, M. and Kattamis, A. and Smith, G. and Habr, D. and Roubert, B. and Taher, A. (2010) Continued improvement in cardiac T2*with deferasirox treatment over 2 years: Results from the extension of epic cardiac substudy in beta-thalassaemia patients with myocardial siderosis. Haematologica-The Hematology Journal, 95 (2). pp. 202-203.
Pennell, D. and Porter, J. and Cappellini, M. and Chan, L.L. and El-Beshlawy, A. and Aydinok, Y. and Ibrahim, H. and Li, C.K. and Viprakasit, V. and Elalfy, M. and Kattamis, A. and Smith, G. and Habr, D. and Roubert, B. and Taher, A. (2010) Deferasirox effectively removes cardiac iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone therapy. Haematologica-The Hematology Journal, 95 (2). p. 699.
Phan, C.L. and Ang, C.H. and Liang, K.L. and Gan, G.G. and Zakaria, Z. and Nadarajan, V. (2010) Identification of unbalanced genomic aberrations by array cgh in chronic myeloid leukemia patients with suboptimal response to imatinib treatment. Haematologica-The Hematology Journal, 95 (2). p. 340.
